Výsledky vyhledávání

Akademický článek

Autor: Nancy Devlin, Michael Herdman, Marco Pavesi, De Phung, Shevani Naidoo, Tomasz M. Beer, Bertrand Tombal, Yohann Loriot, Cristina Ivanescu, Teresa Parli, Mark Balk, Stefan Holmstrom

Publikováno v: Health and Quality of Life Outcomes, Vol 15, Iss 1, Pp 1-9 (2017)

Abstract Background The effect of enzalutamide on health-related quality of life (HRQoL) in the PREVAIL trial in chemotherapy-naïve men with metastatic castration-resistant prostate cancer was analyzed using the generic EQ-5D instrument. Methods Pat

Externí odkaz: https://doaj.org/article/7fd342aa71cd4be5beea27508a11d173

Zobrazit plný text záznamu

Use of PD-1 and PD-L1 Inhibitors after First-Line Therapy in Esophageal Cancer Patients in the US

Autor: Gisoo Barnes, Heather L Handl, Jason C. Allaire, Mark Balk, Soraya Azmi, Keri Yang

Esophageal cancer (EC) makes up 3.2% of all cancers but ranks sixth among cancer-related deaths worldwide. This real-world analysis determined the use of PD-1/PD-L1 (PD[L]1) inhibitors in EC patients after receiving first-line therapy.Newly diagnosed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4312f6de0e6779bc5f98e341d6f856e

Zobrazit plný text záznamu

Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations

Autor: Joseph P. DeAngelis, Scott C. Flanders, J Chambers, Kathryn Fitch, Andrew J. Armstrong, Bruce Brown, Mark Balk, Cat N. Bui, T Goss Sawhney

Publikováno v: Current Medical Research and Opinion. 33:1133-1139

Objective: To estimate the healthcare costs and characteristics of docetaxel chemotherapy episodes of care for men with metastatic castration-resistant prostate cancer (mCRPC). Methods: This study used the Medicare 5% sample and MarketScan Commercial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd86aab2aad8ddda1ad92236409e77db
https://doi.org/10.1080/03007995.2017.1308919

Zobrazit plný text záznamu

Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer

Autor: Mark Balk, Jenny Guo, Cat N. Bui, Yan Song, Arie Barlev, Hongbo Yang, Eric Q. Wu, Bruce Brown, Bhavik J. Pandya, Scott C. Flanders, Marjan Massoudi

Publikováno v: Journal of Medical Economics. 20:121-128

Enzalutamide (ENZA) and abiraterone acetate plus prednisone (AA) are approved second-generation hormone therapies for chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). This study compared ENZA with AA in chemotherapy-naïve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d720fc334a2ebe6b65a3368ff04a120
https://doi.org/10.1080/13696998.2016.1229670

Zobrazit plný text záznamu

Affinity-Guided Design of Caveolin-1 Ligands for Deoligomerization

Autor: Dmitry A. Fishman, Gregory A. Weiss, Kevin M. Johnston, Amanda J. H. Gilliam, Joshua N. Smith, Mark Balk, Sudipta Majumdar, Joshua M. Edgar, Andrew M. Gansmiller, Dylan Flather

Publikováno v: Gilliam, AJH; Smith, JN; Flather, D; Johnston, KM; Gansmiller, AM; Fishman, DA; et al.(2016). Affinity-Guided Design of Caveolin-1 Ligands for Deoligomerization. JOURNAL OF MEDICINAL CHEMISTRY, 59(8), 4019-4025. doi: 10.1021/acs.jmedchem.5b01536. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/84m9p0sc
Journal of medicinal chemistry, vol 59, iss 8

Caveolin-1 is a target for academic and pharmaceutical research due to its many cellular roles and associated diseases. We report peptide WL47 (1), a small, high-affinity, selective disrupter of caveolin-1 oligomers. Developed and optimized through s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::937c3155b2c102d7bd2c8665ac90e660
https://doi.org/10.1021/acs.jmedchem.5b01536

Zobrazit plný text záznamu

Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

Autor: Ken O'Day, Hong Tang, Breanna Popelar, Mark Balk, Cat N. Bui, Linda M. Posta, Peter St. John Francis, Scott Flanders, Nina Oestreicher

Publikováno v: Journal of Managed Care & Specialty Pharmacy. 22:163-170

Prostate cancer is expected to account for approximately one quarter of all new diagnoses of cancer in American men in 2015. The cost of prostate cancer care is expected to reach $15.1 billion by the year 2020, up from $11.9 billion in 2010. Given th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52171c4c52bdc4ebd08218122bf2fbdf
https://doi.org/10.18553/jmcp.2016.22.2.163

Zobrazit plný text záznamu

Subtype-specific modulation of estrogen receptor-coactivator interaction by phosphorylation

Autor: Lidia Nieto, Mark Balk, Christian Haase, Sonja A. Dames, Inga M. Tharun, Wencke Adriaens, Luc Brunsveld, Marcel Scheepstra, Sabine Möcklinghoff

Publikováno v: ACS Chemical Biology, 10(2), 475-484. American Chemical Society

The estrogen receptor (ER) is the number one target for the treatment of endocrine responsive breast cancer and remains a highly attractive target for new drug development. Despite considerable efforts to understand the role of ER post-translational

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80a5054805f9b4f8c4b1488519c49b03
https://doi.org/10.1021/cb5007097

Zobrazit plný text záznamu

Directed evolution and biophysical characterization of a full-length, soluble, human caveolin-1 variant

Autor: Joshua N. Smith, Mariam Iftikhar, J. Mark Balk, Dmitry A. Fishman, Jessica C. Fong, Gregory A. Weiss, Sudipta Majumdar, Joshua M. Edgar, Tivoli J. Olsen

Publikováno v: Biochimica et biophysica acta. Proteins and proteomics. 1866(9)

Protein engineering by directed evolution can alter proteins’ structures, properties, and functions. However, membrane proteins, despite their importance to living organisms, remain relatively unexplored as targets for protein engineering and direc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50dedf5207e0825247aa896dab04ba15
https://pubmed.ncbi.nlm.nih.gov/29857161

Zobrazit plný text záznamu

Autor: Tomasz M. Beer, Bertrand Tombal, Nancy Devlin, Mark Balk, S. Holmstrom, S Naidoo, Teresa Parli, Yohann Loriot, Cristina Ivanescu, De Phung, Marco Pavesi, Michael Herdman

Publikováno v: Health and Quality of Life Outcomes, Vol. 15, no. 1, p. 130-138 (2017)
Health and Quality of Life Outcomes
Health and Quality of Life Outcomes, Vol 15, Iss 1, Pp 1-9 (2017)

Background The effect of enzalutamide on health-related quality of life (HRQoL) in the PREVAIL trial in chemotherapy-naïve men with metastatic castration-resistant prostate cancer was analyzed using the generic EQ-5D instrument. Methods Patients rec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::902e7e4064a58a7b6232fd531495948b
https://hdl.handle.net/2078.1/185758

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání